Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine: Feature

Genomic cancer medicine promises revolutionary change in oncology. The impacts of 'personalized medicine', based upon a molecular classification of cancer and linked to targeted therapies, will extend from individual patient outcomes to the health economy at large. To address the 'who...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2015-12, Vol.20 (12), p.1429-1432
Main Authors: Thomas, David M, Fox, Stephen, Lorgelly, Paula K, Ashley, David, Richardson, Gary, Lipton, Lara, Parisot, John P, Lucas, Mark, McNeil, John
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Genomic cancer medicine promises revolutionary change in oncology. The impacts of 'personalized medicine', based upon a molecular classification of cancer and linked to targeted therapies, will extend from individual patient outcomes to the health economy at large. To address the 'whole-of-system' impact of genomic cancer medicine, we have established a prospective cohort of patients with newly diagnosed cancer in the state of Victoria, Australia, about whom we have collected a broad range of clinical, demographic, molecular, and patient-reported data, as well as data on health resource utilization. Our goal is to create a model for investigating public investment in genomic medicine that maximizes the cost:benefit ratio for the Australian community at large.
ISSN:1359-6446
DOI:10.1016/j.drudis.2015.10.009